PT3587418T - Inibição da proteína de ligação creb (cbp) - Google Patents
Inibição da proteína de ligação creb (cbp)Info
- Publication number
- PT3587418T PT3587418T PT191837418T PT19183741T PT3587418T PT 3587418 T PT3587418 T PT 3587418T PT 191837418 T PT191837418 T PT 191837418T PT 19183741 T PT19183741 T PT 19183741T PT 3587418 T PT3587418 T PT 3587418T
- Authority
- PT
- Portugal
- Prior art keywords
- creb
- cbp
- inhibition
- binding protein
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692593P | 2018-06-29 | 2018-06-29 | |
| PCT/US2018/051214 WO2019055869A1 (en) | 2017-09-15 | 2018-09-14 | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
| PCT/US2018/051235 WO2019055877A1 (en) | 2017-09-15 | 2018-09-14 | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
| US201962819490P | 2019-03-15 | 2019-03-15 | |
| US16/457,596 US10870648B2 (en) | 2018-06-29 | 2019-06-28 | Inhibiting CREB binding protein (CBP) |
| PCT/US2019/039936 WO2020006483A1 (en) | 2018-06-29 | 2019-06-28 | Inhibiting creb binding protein (cbp) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3587418T true PT3587418T (pt) | 2021-12-02 |
Family
ID=68987627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT191837418T PT3587418T (pt) | 2018-06-29 | 2019-07-01 | Inibição da proteína de ligação creb (cbp) |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10870648B2 (OSRAM) |
| EP (1) | EP3998266A1 (OSRAM) |
| JP (4) | JP6781806B2 (OSRAM) |
| KR (2) | KR20250067962A (OSRAM) |
| CN (2) | CN116178369A (OSRAM) |
| AU (3) | AU2019295790B2 (OSRAM) |
| BR (1) | BR112020026783A2 (OSRAM) |
| CA (1) | CA3105099A1 (OSRAM) |
| CY (1) | CY1124762T1 (OSRAM) |
| DK (1) | DK3587418T3 (OSRAM) |
| ES (1) | ES2900105T3 (OSRAM) |
| HR (1) | HRP20211698T1 (OSRAM) |
| HU (1) | HUE056885T2 (OSRAM) |
| IL (3) | IL321337A (OSRAM) |
| LT (1) | LT3587418T (OSRAM) |
| MA (1) | MA50675B1 (OSRAM) |
| MX (2) | MX2020014303A (OSRAM) |
| PL (1) | PL3587418T3 (OSRAM) |
| PT (1) | PT3587418T (OSRAM) |
| RS (1) | RS62732B1 (OSRAM) |
| SA (1) | SA520420909B1 (OSRAM) |
| SG (1) | SG11202012767UA (OSRAM) |
| SI (1) | SI3587418T1 (OSRAM) |
| SM (1) | SMT202100636T1 (OSRAM) |
| WO (1) | WO2020006483A1 (OSRAM) |
| ZA (2) | ZA202100509B (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020026783A2 (pt) * | 2018-06-29 | 2021-03-30 | Forma Therapeutics, Inc. | Inibição da proteína de ligação creb (cbp) |
| AU2020241709B2 (en) * | 2019-03-15 | 2025-12-04 | Forma Therapeutics, Inc. | Compositions and methods for treating androgen receptor positive forms of cancer |
| EP3937940A4 (en) | 2019-03-15 | 2022-12-21 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (creb) |
| MX2022016496A (es) | 2020-06-25 | 2023-02-22 | Tolremo Therapeutics Ag | Combinacion de un inhibidor del bromodominio cbp/p300 y un inhibidor del egfr para su uso en el tratamiento de la cpnm con mutacion del egfr. |
| BR112022026186A2 (pt) | 2020-06-25 | 2023-01-17 | Tolremo Therapeutics Ag | Combinação de um inibidor de bromodomínio cbp/p300 e um inibidor de kras |
| US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
| US11795168B2 (en) * | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4404207A (en) | 1981-11-06 | 1983-09-13 | Riker Laboratories, Inc. | Antimicrobial 8-substituted benzo [IJ]quinolizines |
| US5138089A (en) * | 1986-06-27 | 1992-08-11 | The Procter & Gamble Company | Chromophores, sunscreen compositions and methods for preventing sunburn |
| WO1995020589A1 (en) | 1994-01-28 | 1995-08-03 | Cell Therapeutics, Inc. | Cell signaling inhibitors |
| US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| US6455564B1 (en) | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
| US7101869B2 (en) | 1999-11-30 | 2006-09-05 | Pfizer Inc. | 2,4-diaminopyrimidine compounds useful as immunosuppressants |
| US7345051B2 (en) | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
| ATE401383T1 (de) | 2000-11-20 | 2008-08-15 | Merck Patent Gmbh | Chirale photoisomerisierbare verbindungen |
| WO2003033517A1 (en) | 2001-10-17 | 2003-04-24 | The University Of British Columbia | Ship 1 modulators |
| AU2002349477A1 (en) | 2001-11-26 | 2003-06-10 | Takeda Chemical Industries, Ltd. | Bicyclic derivative, process for producing the same, and use |
| HUP0203976A3 (en) | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| TWI322012B (en) | 2002-12-20 | 2010-03-21 | Organon Nv | Tetrahydroquinoline derivatives |
| IN2003CH00929A (OSRAM) | 2003-11-13 | 2008-10-06 | ||
| WO2005066162A1 (en) | 2003-12-23 | 2005-07-21 | Human Biomolecular Research Institute | Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer |
| JP4790703B2 (ja) | 2004-04-07 | 2011-10-12 | 武田薬品工業株式会社 | 環式化合物 |
| WO2005105814A1 (en) | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| US20080318989A1 (en) | 2005-12-19 | 2008-12-25 | Burdick Daniel J | Pyrimidine Kinase Inhibitors |
| US20070203236A1 (en) | 2006-01-11 | 2007-08-30 | Smith Jeffrey W | Novel antagonists of the human fatty acid synthase thioesterase |
| US20080075692A1 (en) | 2006-05-09 | 2008-03-27 | Perrine Susan P | Methods for treating blood disorders |
| EP1878724A1 (en) | 2006-07-15 | 2008-01-16 | sanofi-aventis | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles |
| CA2574531C (en) | 2007-01-19 | 2016-10-25 | The University Of British Columbia | Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity |
| IN2014MN02330A (OSRAM) | 2007-06-21 | 2015-08-14 | Wistar Inst | |
| WO2009000413A1 (en) | 2007-06-26 | 2008-12-31 | Sanofi-Aventis | A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles |
| WO2009001817A1 (ja) | 2007-06-27 | 2008-12-31 | Taisho Pharmaceutical Co., Ltd. | １１β－ＨＳＤ１阻害活性を有する化合物 |
| TW200930369A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
| AR072008A1 (es) | 2008-06-13 | 2010-07-28 | Merck & Co Inc | Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38 |
| LT2303021T (lt) | 2008-06-16 | 2019-06-25 | University Of Tennessee Research Foundation | Junginiai, skirti vėžio gydymui |
| US9334242B2 (en) | 2008-06-16 | 2016-05-10 | Gtx, Inc. | Compounds for treatment of cancer |
| US8604030B2 (en) * | 2009-03-27 | 2013-12-10 | Kowa Company, Ltd. | Fused piperidine compound and pharmaceutical containing same |
| WO2010118208A1 (en) | 2009-04-09 | 2010-10-14 | Exelixis, Inc. | Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer |
| WO2010120112A2 (en) | 2009-04-15 | 2010-10-21 | Choongwae Pharma Corporation | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof |
| WO2010138490A1 (en) | 2009-05-26 | 2010-12-02 | Exelixis, Inc. | Benzoxazepines as inhibitors of mtor and methods of their use and manufacture |
| NZ596552A (en) | 2009-05-26 | 2014-02-28 | Exelixis Inc | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture |
| US9005670B2 (en) | 2010-01-05 | 2015-04-14 | The Johns Hopkins University | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies |
| NZ603789A (en) * | 2010-05-26 | 2015-03-27 | Sunovion Pharmaceuticals Inc | Heteroaryl compounds and methods of use thereof |
| US8906943B2 (en) | 2010-08-05 | 2014-12-09 | John R. Cashman | Synthetic compounds and methods to decrease nicotine self-administration |
| JP5937102B2 (ja) | 2010-12-14 | 2016-06-22 | エレクトロフォレティクス リミテッド | カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤 |
| US8765978B2 (en) | 2010-12-16 | 2014-07-01 | Transitions Optical, Inc. | Method of making indeno-fused naphthol materials |
| EP2678050B1 (en) | 2011-02-24 | 2020-10-14 | Emory University | Noggin blocking compositions for ossification and methods related thereto |
| TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| WO2013148114A1 (en) | 2012-03-30 | 2013-10-03 | University Of Florida Research Foundation, Inc. | P300/cbp inhibitors and methods of use |
| US9211333B2 (en) | 2012-06-05 | 2015-12-15 | Hong Kong Baptist University | Anti-cancer agents synthesized based on miliusane compounds |
| WO2014045305A1 (en) | 2012-09-21 | 2014-03-27 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| RU2543485C2 (ru) | 2013-02-26 | 2015-03-10 | Андрей Александрович Иващенко | Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| PL3010503T3 (pl) | 2013-06-21 | 2020-08-24 | Zenith Epigenetics Ltd. | Nowe bicykliczne inhibitory bromodomen |
| WO2015004533A2 (en) | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| CA2918910A1 (en) | 2013-07-25 | 2015-01-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| DE102013215912B3 (de) | 2013-08-12 | 2015-02-26 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung |
| TW201605859A (zh) | 2013-11-14 | 2016-02-16 | 必治妥美雅史谷比公司 | 作為酪蛋白激酶１δ／ε抑制劑之新穎經取代之吡唑并－哌 |
| CN106029076B (zh) | 2013-11-18 | 2019-06-07 | 福马疗法公司 | 作为bet溴域抑制剂的苯并哌嗪组合物 |
| NZ720004A (en) | 2013-11-18 | 2020-03-27 | Forma Therapeutics Inc | Tetrahydroquinoline compositions as bet bromodomain inhibitors |
| JP2017529358A (ja) | 2014-09-19 | 2017-10-05 | ジェネンテック， インコーポレイテッド | がんの処置のためのｃｂｐ／ｅｐ３００阻害剤およびｂｅｔ阻害剤の使用 |
| WO2016086200A1 (en) | 2014-11-27 | 2016-06-02 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
| US10435402B2 (en) | 2015-01-08 | 2019-10-08 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| WO2016128908A1 (en) | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| WO2017197240A1 (en) | 2016-05-12 | 2017-11-16 | The Regents Of The University Of Michigan | Ash1l inhibitors and methods of treatment therewith |
| MA45122A (fr) | 2016-05-24 | 2019-04-10 | Constellation Pharmaceuticals Inc | Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer |
| GB201617627D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201617630D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| TW202332436A (zh) * | 2017-04-18 | 2023-08-16 | 美商塞爾基因定量細胞研究公司 | 治療用化合物 |
| TWI795440B (zh) * | 2017-09-15 | 2023-03-11 | 美商佛瑪治療公司 | 作為ＣＢＰ／ｐ３００抑制劑之四氫─咪唑並喹啉化合物 |
| BR112020026783A2 (pt) * | 2018-06-29 | 2021-03-30 | Forma Therapeutics, Inc. | Inibição da proteína de ligação creb (cbp) |
-
2019
- 2019-06-28 BR BR112020026783-0A patent/BR112020026783A2/pt unknown
- 2019-06-28 IL IL321337A patent/IL321337A/en unknown
- 2019-06-28 AU AU2019295790A patent/AU2019295790B2/en active Active
- 2019-06-28 MX MX2020014303A patent/MX2020014303A/es unknown
- 2019-06-28 WO PCT/US2019/039936 patent/WO2020006483A1/en not_active Ceased
- 2019-06-28 SG SG11202012767UA patent/SG11202012767UA/en unknown
- 2019-06-28 MX MX2023013508A patent/MX2023013508A/es unknown
- 2019-06-28 KR KR1020257014745A patent/KR20250067962A/ko active Pending
- 2019-06-28 IL IL279734A patent/IL279734B2/en unknown
- 2019-06-28 CA CA3105099A patent/CA3105099A1/en active Pending
- 2019-06-28 US US16/457,596 patent/US10870648B2/en active Active
- 2019-06-28 KR KR1020217002866A patent/KR102805503B1/ko active Active
- 2019-06-28 CN CN202211658329.8A patent/CN116178369A/zh active Pending
- 2019-06-28 CN CN201980050022.XA patent/CN112513038B/zh active Active
- 2019-07-01 HR HRP20211698TT patent/HRP20211698T1/hr unknown
- 2019-07-01 DK DK19183741.8T patent/DK3587418T3/da active
- 2019-07-01 PL PL19183741T patent/PL3587418T3/pl unknown
- 2019-07-01 RS RS20211321A patent/RS62732B1/sr unknown
- 2019-07-01 HU HUE19183741A patent/HUE056885T2/hu unknown
- 2019-07-01 SM SM20210636T patent/SMT202100636T1/it unknown
- 2019-07-01 EP EP21193994.7A patent/EP3998266A1/en active Pending
- 2019-07-01 PT PT191837418T patent/PT3587418T/pt unknown
- 2019-07-01 ES ES19183741T patent/ES2900105T3/es active Active
- 2019-07-01 JP JP2019123100A patent/JP6781806B2/ja active Active
- 2019-07-01 MA MA50675A patent/MA50675B1/fr unknown
- 2019-07-01 SI SI201930136T patent/SI3587418T1/sl unknown
- 2019-07-01 LT LTEP19183741.8T patent/LT3587418T/lt unknown
-
2020
- 2020-05-28 JP JP2020093126A patent/JP7017801B2/ja active Active
- 2020-06-08 US US16/946,159 patent/US11254674B2/en active Active
- 2020-12-17 JP JP2020209005A patent/JP2021042255A/ja not_active Withdrawn
- 2020-12-28 SA SA520420909A patent/SA520420909B1/ar unknown
-
2021
- 2021-01-25 ZA ZA2021/00509A patent/ZA202100509B/en unknown
- 2021-11-22 CY CY20211101010T patent/CY1124762T1/el unknown
-
2022
- 2022-02-10 US US17/669,112 patent/US12378242B2/en active Active
- 2022-09-23 ZA ZA2022/10560A patent/ZA202210560B/en unknown
-
2023
- 2023-09-05 AU AU2023226653A patent/AU2023226653B2/en active Active
-
2024
- 2024-06-09 IL IL313466A patent/IL313466B2/en unknown
-
2025
- 2025-03-21 JP JP2025046918A patent/JP2025094157A/ja active Pending
- 2025-07-29 AU AU2025210762A patent/AU2025210762A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3587418T (pt) | Inibição da proteína de ligação creb (cbp) | |
| MA53921A (fr) | Inhibiteurs de protéine tyrosine phosphatase | |
| CL2020000173S1 (es) | Masajeador. | |
| EP3928275A4 (en) | MICROLOAN SYSTEM | |
| EP3845717A4 (en) | PARTITION WALL | |
| CL2021000426A1 (es) | Inhibidores de la interacción proteína-proteína keap1-nrf2. | |
| EP3813341A4 (en) | TERMINAL DEVICE | |
| EP3838108A4 (en) | ENDOSCOPE SYSTEM | |
| IL280890A (en) | Antigen-binding proteins targeting shared antigens | |
| EP3817150A4 (en) | Connector component | |
| IL283900A (en) | Pharmaceutical combinations | |
| EP3897128A4 (en) | ANTIMICROBIAL PEPTIDES | |
| DK3781726T3 (da) | Fotovoltaisk-elektrokemisk (pv-ec) system | |
| EP4069093A4 (en) | Bioprinting system | |
| EP3758342A4 (en) | TERMINAL DEVICE | |
| EP3877335A4 (en) | Aluminosilicate zeolite intergrowths | |
| DK3775477T3 (da) | Brøndområdeisoleringssystem | |
| EP3979930C0 (en) | MICRO-INTRODUCER SYSTEM | |
| EP3892299A4 (en) | Immunosuppressant | |
| EP3877759C0 (en) | CHROMATOGRAPHY COMPONENT | |
| EP4037450A4 (en) | Component mounting system | |
| EP3773102A4 (en) | DONORS | |
| CL2019000242S1 (es) | Cubierta de parrilla. (divisional solicitud 795-2018) | |
| PL3741550T3 (pl) | Układ | |
| EP3899252C0 (en) | DETUNER SYSTEM |